Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
25 January 2017Website:
http://www.leaptx.comNext earnings report:
13 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 20 min agoDividend
Analysts recommendations
Institutional Ownership
LPTX Latest News
Biotech stocks are some of my favorite stocks to watch and invest in for a couple of reasons.
Leap Therapeutics (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
30% ORR and 93% DCR across heterogenous second-line CRC patients treated with DKN-01 plus bevacizumab and chemotherapy Subgroup analysis reveals greatest benefit in left-sided tumors, particularly rectal and rectosigmoid patients with 46% ORR, 100% DCR, and preliminary median PFS of 9.4 months. Leap to host conference call to report additional clinical data including further subgroup analyses on Tuesday, January 23, 2024 at 8:30 a.m.
19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient with partial response, resulting in 73% ORR in overall mITT population, including 86% ORR in PD-L1-low patients CAMBRIDGE, Mass. , May 25, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting new long-term follow-up data in first-line patients with advanced gastric or gastroesophageal junction adenocarcinoma (GEA) from Part A of the DisTinGuish study, a Phase 2 clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with BeiGene's tislelizumab and chemotherapy, at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL on June 2-6, 2023.
Penny stocks under $1 to watch this week. The post 3 Hot Penny Stocks To Watch Under $1, Time To Buy?
What type of business is Leap Therapeutics?
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
What sector is Leap Therapeutics in?
Leap Therapeutics is in the Healthcare sector
What industry is Leap Therapeutics in?
Leap Therapeutics is in the Biotechnology industry
What country is Leap Therapeutics from?
Leap Therapeutics is headquartered in United States
When did Leap Therapeutics go public?
Leap Therapeutics initial public offering (IPO) was on 25 January 2017
What is Leap Therapeutics website?
https://www.leaptx.com
Is Leap Therapeutics in the S&P 500?
No, Leap Therapeutics is not included in the S&P 500 index
Is Leap Therapeutics in the NASDAQ 100?
No, Leap Therapeutics is not included in the NASDAQ 100 index
Is Leap Therapeutics in the Dow Jones?
No, Leap Therapeutics is not included in the Dow Jones index
When was Leap Therapeutics the previous earnings report?
No data
When does Leap Therapeutics earnings report?
The next expected earnings date for Leap Therapeutics is 13 November 2024